Modafinil Online Australia (trade name Provigil) is a wake-promoting agent that improves symptoms of narcolepsy and obstructive sleep apnea/hypopnea syndrome. It also reduces daytime sleepiness in patients with shift work disorder.
Patients with mild to moderate obstructive sleep apnea/hypopnea frequently experience residual daytime sleepiness despite treatment with nasal continuous positive airway pressure. Modafinil significantly improved ESS and multiple sleep latency test scores in these patients.
The sleep disorder narcolepsy causes excessive daytime sleepiness, which may cause you to fall asleep at inappropriate times. It can also affect your ability to perform tasks, especially during the night or at work.
Narcolepsy is a chronic condition, but you can manage it with medication and lifestyle changes. You can also join a support group for narcolepsy to share your experiences and get ideas from other people who have the condition.
To control your narcolepsy, your doctor may prescribe a stimulant or a sedative. Modafinil is the first choice for most doctors because it has few side effects and doesn’t interact with many other medications. It is also less addictive than older stimulants such as methylphenidate (Ritalin) and amphetamines. It is also a good choice for those with cataplexy since it works well to control that symptom.
In large-scale, double-blind placebo-controlled clinical studies in patients with narcolepsy and shift work sleep disorder, Modalert 200 Mg significantly improved wakefulness on the MSLT and MWT.
It also improved patient-reported sleepiness on the ESS and KSS and health-related quality of life, which was sustained over 40 weeks. In addition, Modafinil was absorbed and metabolized rapidly, with steady-state plasma concentrations reached within 4 days. The drug is eliminated primarily by the liver and excreted as metabolites in the urine.
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is frequently associated with excessive diurnal somnolence that can be treated effectively with modafinil. Two large-scale randomized placebo-controlled studies have shown that modafinil improves objectively determined sleep latency, subjective daytime sleepiness, and functional status outcomes, including fatigue, in patients with OSA or shift work disorder.
These improvements are mediated by the wake-promoting activity of modafinil. It binds weakly but selectively to the dopamine transporter and, to a lesser extent, to the norepinephrine transporter in certain brain regions, which increases extracellular concentrations of monoamines such as dopamine and norepinephrine (Mignot et al 1994; Nishino et al 1998; Madras et al 2006).
Despite its wake-promoting activity, modafinil is not an effective suppressor of REM sleep or scheduled sleep time. However, its use as an adjunct to standard therapies that treat underlying airway obstruction is a clinically important option for these patients.
In a double-blind study, the use of modafinil improved Epworth sleepiness scale (ESS) scores and performance on a portable AusEd driving simulator, as well as FOSQ sleepiness-related quality of life score in patients with mild to moderate OSA who had significant daytime sleepiness (mean net improvement over placebo 3.6 points, 95% CI 1.3 to 5.8, p=0.003). Neither baseline sleep apnoea severity nor baseline ESS improvement was a significant predictor of treatment response (test for interaction p=0.108).
In a long-term open-label extension study, modafinil ( Modvigil 200 mg ) was shown to be effective in treating residual excessive daytime sleepiness in OSA patients who continued to receive continuous positive airway pressure therapy.
Despite the presence of residual daytime sleepiness, adherence to CPAP treatment was high and modafinil was generally well tolerated, with infection, headache, and nervousness being the most common adverse events.
Shift work sleep disorder
Shift work sleep disorder (SWSD) is a common condition that affects people who have night shift or rotating shift jobs. This disorder causes difficulty falling asleep and staying awake during the daytime, and it can make it difficult to function at work or home. It can also cause other health problems, like heart disease and obesity.
SWSD can be treated by changing habits and using stimulants like Modafinil. A doctor will typically diagnose SWSD based on a patient’s symptoms and by asking questions about their sleeping patterns. They may also ask for a sleep diary. If the doctor suspects that another health problem is causing the SWSD, they might perform a sleep study or other diagnostic tests to confirm the diagnosis.
A patient with SWSD who takes Modafinil will typically take the pill once a day with or without food. They should usually take the pill in the morning, ideally around 1 hour before their work starts. They should not change their schedule or the time of day they take the pill without talking to their doctor first.
Studies show that patients with SWSD who took Modafinil had improved objectively measured wakefulness and reduced subjective sleepiness compared to those who took a placebo. However, these changes were not permanent. This is why it’s important to follow good sleep hygiene, like sleeping in a dark and quiet room and avoiding caffeine close to bedtime.
Fatigue is a common problem that can be caused by many factors. These include work stress, lack of exercise, and poor diet. It is also a common symptom of some diseases, such as multiple sclerosis and chronic fatigue syndrome. Taking the right medications can help relieve fatigue and increase energy levels. Your doctor may also recommend a fatigue diary to help you identify patterns in your symptoms.
Modafinil is a novel wake-promoting agent that has been shown to improve EDS associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea. It is also being investigated as a treatment for fatigue and EDS associated with neurological disorders.
A recent meta-analysis of six trials comparing placebo to 200 mg/day modafinil showed that the drug improved objectively measured wakefulness on the MWT and subjective sleepiness scores on the ESS. It also improved FOSQ total and subscale scores for vigilance and general productivity but not social outcomes or intimacy.
Modafinil has been shown to block a mechanism in the brain that removes dopamine, which is a neurotransmitter associated with feeling happy and alert. Researchers believe this explains why the drug makes people feel more awake. It also has an antioxidant effect, which may protect the brain against oxidative damage. Read More Blog…